The leadership of Bladder Cancer has disclosed the following information in keeping with the journal's disclosure policy.
Seth P. Lerner, MD, Editor-in-Chief
Advisory Board: FerGene, Pfizer. BMS, Incyte
Consultant: Vaxiion, Verity, Protara, C2i Genomics, Ferring, Aura Bioscience, Surge Therapeutics
Clinical Trials: Genentech (SWOG), Vaxiion, Endo, FKD, JBL (SWOG), Merck (Alliance), Aura Bioscience, Surge Therapeutics, QED Therapeutics
Licenses/Patents: TCGA Classifier
Other: UroToday (honoraria), IOS Press (editorial responsibilities, compensated), co-editor bladder cancer section UpToDate, Grand Rounds Urology (Honoraria)
Dan Theodorescu, MD, PhD, Editor-in-Chief
Consultant: Machavert, Merck, Urogen
Honoraria: Machavert, Merck, Urogen
Licenses/Patents: University of Colorado
Research Support: None
Stockholder in: None
Other: IOS Press (editorial responsibilities, compensated)
Hikmat A. Al-Ahmadie, MD, Associate Editor
Consultant: AstraZeneca, Paige.AI
Yves Allory, MD, PhD, Associate Editor
Consultant: AstraZeneca, Janssen, MSD, VitaDx
Invited Speaker : Astellas, AstraZeneca, Bristol-Myers Squibb, MSD, Sanofi
COBLAnCE Cohort Support: Bristol-Myers Squibb, MS
Public and Charity Fundings: INCa, ANR, Ligue Contre le Cancer, Fondation ARC
Andrea B. Apolo, MD, Associate Editor
Nothing to disclose
Piyush K. Agarwal, MD, Associate Editor
Advisory Board (paid): AURA, Verity, UROGEN, Janssen, AstraZeneca, PeerView, Nonagen Therapeutics.
Rebecca Johnson, MPH, Associate Editor
Nothing to disclose
Joaquim Bellmunt, MD, PhD, Associate Editor
Consultant or Advisory Role: Pierre Fabre, Astellas Pharma, Pfizer, Merck, Genentech, Novartis, AstraZeneca/MedImmune, Bristol-Myers Squibb
Research Funding: Millennium, Sanofi, Pfizer/EMD Serono
Stocks: Rainier
Travel, Accommodations, Expenses: Pfizer, MSD Oncology, Ipsen
Karim Chamie, MD, Associate Editor
Consultant: Urogen Pharma, ImmunityBio
Research Funding: Urogen Pharma, Merck
Speaker: BMS
Advisory Board: Urogen Pharma, BMS, ImmunityBio
David J. DeGraff, PhD, Associate Editor
Nothing to disclose
Lars Dyrskjøt, PhD, Associate Editor
Consultant: Ferring, MSD, UroGen
Speaker Honoraria: AstraZeneca, Pfizer and Roche
Clinical Trials: Roche
Other Research Support: C2i Genomics, Natera, Ferring, AstraZeneca, Photocure
Travel support: MSD
Board member: BioXpedia
Jason A. Efstathiou, MD, PhD, Associate Editor
Consultant: Blue Earth Diagnostics, Boston Scientific, AstraZeneca
Scientific Advisory Board: Merck, Myovant Sciences, Roivant Pharma, Progenics, Janssen
Bishoy M. Faltas, MD, Associate Editor
Honoraria: Springer Nature, UroToday
Clinical Trials: Eli-Lilly
Thomas Flaig, MD, Associate Editor
Consultant: Seattle Genetics, Janssen Oncology
Clinical Trials: Novartis,Bavarian Nordic, Dendreon, GTx, Janssen Oncology, Medivation, Sanofi, Pfizer, Bristol-Myer's Squibb, Seattle Genetics, Merck, Roche/Genentech, Exelixis, Aragon Pharmaceuticals, Tokai Pharmaceuticals, AstraZeneca/MedImmune, Lilly, Astellas Pharma, Agensys, La Roche-Posay
Other: Leadership: Aurora Oncology
Licenses/Patents: University of Colorado - 2 bladder cancer therapeutics (not in clinical trial)
Stockholder: Aurora Oncology
Donna Hansel, MD, PhD, Associate Editor
Consultant: AstraZeneca, Merck, Janssen
Other Research Support: Konica Minolta
Other: Genentech, AstraZeneca, Taris
Arndt Hartmann, MD, Associate Editor
Advisory Board: BMS, MSD, Roche, Cepheid, Qiagen, Janssen, Astra Zeneca, Agilent, Lilly, Phäon
Consultant: BMS, MSD, Roche, Astra Zeneca, Novartis, Boehringer Ingelheim, Abbvie, Cepheid, Nanostring, Illumina, Qiagen, Biontech, Janssen, 3D Histotech, Diaceutics
Clinical Trials: Janssen, Cepheid, AstraZeneca, Roche
Speaker Honoraria: BMS, MSD, Roche, Astra Zeneca, Boehringer Ingelheim, Abbvie, Janssen, Pfizer
Other Research Support: Illumina, Cepheid, Biotech, Roche, Janssen, Nanostring AstraZeneca
Anne Kiltie, MA, DM, DSc, Associate Editor
Research Funding: NHS Grampian Endowments Fund. Friends of ANCHOR
William Y. Kim, MD, Associate Editor
Stock and Other Ownership Interests: Abbvie, Amgen, Apellis, Arvinas, BeiGene, Bristol-Myers Squibb, Eli Lilly, Moderna, Natera, Novo Nordisk, Revolution Med, Tango, Viking, Focal Medical
Consulting or Advisory Role: OncoRev, Focal Medical
Research Funding: Merck
Patents, Royalties, Other Intellectual Property:PurIST Classifier (pancreatic cancer subtypes) and DeCAF Classifier (pancreatic cancer CAF subtypes).
Yair Lotan, MD, Associate Editor
Consultant or Advisory Role: Nanorobotics, C2I genomics, Photocure, Astra-Zeneca, Merck, Fergene, Abbvie, Nucleix, Ambu, Seattle Genetics, Hitachi, Ferring Research, verity pharmaceutics, virtuoso surgical, Stimit, Urogen, Vessi medical, CAPs medical, Xcures, BMS, Nonagen, Aura Biosciences, Inc., Convergent Genomics, Pacific Edge, Pfizer, Phinomics Inc, CG oncology, Uroviu, On target lab
Stock options: Vessi Medical, CAPs medical, C2I genomics, Nanorobot, Phinomics Inc, Uroviu
S. Bruce Malkowicz, MD, Associate Editor
Consultant: Pacific Edge
Clinical Trial Investigator: Merck
Surena F. Matin, MD, Associate Editor
Speaker: Ology Education, Urogen (ended Sep 2020)
Consultant: Urogen (ended Sep 2020), Simon, Kucher and partners (ended Jan 2020)
David McConkey, PhD, Associate Editor
Grant Support: Astra-Zeneca, Rainier Pharmaceuticals
Honoraria: Janssen, H3 Biomedicine, Rainier Pharmaceuticals
Edward M. Messing, MD, Associate Editor
Nothing to disclose
Matt Milowsky, MD, Associate Editor
Research Funding: Merck, Roche/Genentech, Bristol-Myers Squibb, Astellas Pharma, Clovis Oncology, Inovio Pharmaceuticals, AstraZeneca, Mirati Therapeutics, Constellation Pharmaceuticals, Syndax, Incyte, Seagen, Amgen, Regeneron, Arvinas, Pfizer, Innocrin, Johnson & Johnson
Consultant (honoraria paid to institution): Asieris
Valeria Panebianco, MD, Associate Editor
Nothing to disclose
Francisco X. Real, MD, PhD, Associate Editor
Research Funding: Janssen
Bas W.G. van Rhijn, MD, PhD, Associate Editor
Advisory Board Meetings: QED Therapeutics (2021-June)
Incyte International Biosciences (2022-Oct.)
Maria J.Ribal. MD, PhD Associate Editor
Clinical Trials: Bayer, Janssen, Unicancer, Astellas, Seagen, UroGen Pharma, Fidia, DMIA
Speaker Honoraria: Astellas, Johnson and Johnson
Patents (intellectual property only): METODO DE DIAGNOSTICO NO INVASIVO DE CANVER DE VEJIGA. Inventores: Antonio Alcaraz Lourdes Mengual, Maria Jose Ribal, Juan Jose Lozano. Oficina de patente: European Patent Office. Numero de concesion: 13382030.8-1403. Entidad titular: Fina Biotech, S.L.U. Junio 2007
Gottfrid Sjödahl, PhD, Associate Editor
Nothing to disclose
Mark S. Soloway, MD, Associate Editor
Nothing to disclose
Cora N. Sternberg, MD, Associate Editor
Consultant: Pfizer, Merck Ga, MSD, AstraZeneca, Astellas Pharma, Sanofi -Genzyme, Roche/Genentech, Immunomedics now Gilead, Amgen, Clovis Oncology, Bayer, Bristol Myers Squibb, Seattle Genetics, Impact Therapeutics, Janssen, Foundation Medicine, UroToday, Medscape
Jeremy Teoh, MD, Associate Editor
Honorarium / Lecture: Astellas, Boston Scientific, Combat Medical, Ferring, Ipsen, Janssen, Olympus, Sanofi.
Consultant /Advisory board: Astellas, CMR Robotics, Combat Medical, Ferring, Janssen, MRI PRO, Phase Scientific, Procept BioRobotics.
Research Grant: Baxter, Bristol-Myers Squibb, Ferring, Janssen, Merck Sharp & Dohme, Storz, Olympus.
George Thalmann, MD, Associate Editor
Nothing to declare
Xue-Ru Wu, MD, Associate Editor
Nothing to disclose
Alexandre R. Zlotta, MD, PhD, Associate Editor
Consultant: AstraZeneca, Ferring, Janssen, Sanofi, Verity Pharma, Merck
Last updated: Jun 27, 2023
